share_log

Stifel Downgrades RxSight to Hold, Lowers Price Target to $40

Benzinga ·  Dec 20 18:54  · Ratings

Stifel analyst Thomas Stephan downgrades RxSight (NASDAQ:RXST) from Buy to Hold and lowers the price target from $65 to $40.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment